65,437 trials
Phase 1: Pain Management · Phase 2: Pain Management
Primary: Phase 1: Number of Participants With Adverse Events Related, Not Related and Serious Events Related to Paracetamol — 0; 0; 0; 1 participants
Postoperative Pain
Primary: Mean Pain Intensity on Movement AUC (Time Normalized Area Under the Curve) During the Period 0 to 72 Hours Post-dose. — 5.35; 5.81 score on a scale — p=0.303
Alzheimer Disease
Primary: Change From Baseline in CSF Abeta42 — 4.8; 12.5; 16.2 pg/mL — p=0.087
Post Operative Surgical Site Infection
Primary: Number of Clinically Significant Deep Surgical Site Infection (SSI) — 29; 48; 1; 1 surgical site infections
Locally Recurrent Breast Cancer · Metastatic Breast Cancer
Primary: Kaplan-Meier Estimate of Overall Survival: Intention to Treat (ITT) Population — 12.4; 10.3 Months — p== 0.0835
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Postoperative Pain
Primary: Pain Intensity (PI) — 4.15; 4.46; 4.27 score on a scale — p=0.467
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Obstructive Sleep Apnea
Primary: Toffee Mask Usability — 33; 1; 4 Participants
Muscular Atrophy, Spinal
Primary: Hammersmith Functional Motor Scale Expanded (HFMSE) Summary Statistics and Mixed Model Analysis — 0.208; -0.583 Overall Score — p=0.0083
Healthy Volunteers
Primary: Group 1: Observed Maximum Plasma Concentration (Cmax) of Apremilast — 409.96; 267.85; 329.78; 345.11 ng/mL
Diabetes Mellitus
Primary: HgbA1c — 8.5; 8.5; 7.99; 8.2 percentage of glycated hemoglobin
Controlled Ovarian Simulation
Primary: Ongoing Pregnancy Rate — 31.3; 25.7 percentage of participants
Neuralgia, Postherpetic
Primary: Change From Baseline in Average Daily Pain Numeric Rating Scale (NRS) Score at Week 6 — 6.40; 6.42; 6.39; -1.22 units on a scale — p=0.687
Colorectal Neoplasms · Melanoma · Prostatic Neoplasms
Primary: Safety Endpoints: Serious Adverse Events to Tremelimumab. — 4; 33 Participants